Joseph W Chow
Overview
Explore the profile of Joseph W Chow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
747
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carmeli Y, Cisneros J, Paul M, Daikos G, Wang M, Torre-Cisneros J, et al.
Lancet Infect Dis
. 2024 Oct;
25(2):218-230.
PMID: 39389071
Background: There is a need for additional therapeutic options for serious infections caused by Gram-negative pathogens. In the phase 3, descriptive REVISIT study, we investigated the safety and efficacy of...
2.
Mazuski J, Wagenlehner F, Torres A, Carmeli Y, Chow J, Wajsbrot D, et al.
Infect Dis Ther
. 2021 Aug;
10(4):2399-2414.
PMID: 34374952
Introduction: This exploratory analysis assessed efficacy and safety outcomes in patients with Gram-negative bacteremia treated with ceftazidime-avibactam or comparator across five phase 3, randomized, controlled, multi-center trials in adults with...
3.
Cheng K, Newell P, Chow J, Broadhurst H, Wilson D, Yates K, et al.
Drug Saf
. 2020 Jul;
43(8):751-766.
PMID: 32602065
Introduction: Ceftazidime-avibactam combines the established anti-pseudomonal cephalosporin, ceftazidime, with the novel non-β-lactam β-lactamase inhibitor, avibactam. Objectives: The aim of this study was to evaluate the safety of ceftazidime-avibactam in adults...
4.
Stone G, Bradford P, Tawadrous M, Taylor D, Cadatal M, Chen Z, et al.
Antimicrob Agents Chemother
. 2020 Feb;
64(5).
PMID: 32071051
Nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), is increasingly associated with multidrug-resistant Gram-negative pathogens. This study describes the activity of ceftazidime-avibactam, ceftazidime, and relevant comparator agents against bacterial pathogens isolated...
5.
Stone G, Newell P, Gasink L, Broadhurst H, Wardman A, Yates K, et al.
J Antimicrob Chemother
. 2018 Jun;
73(9):2519-2523.
PMID: 29912399
Objectives: This analysis evaluated the clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa isolates pooled from the adult Phase III clinical trials in patients with complicated intra-abdominal infection...
6.
Torres A, Zhong N, Pachl J, Timsit J, Kollef M, Chen Z, et al.
Lancet Infect Dis
. 2017 Dec;
18(3):285-295.
PMID: 29254862
Background: Nosocomial pneumonia is commonly associated with antimicrobial-resistant Gram-negative pathogens. We aimed to assess the efficacy and safety of ceftazidime-avibactam in patients with nosocomial pneumonia, including ventilator-associated pneumonia, compared with...
7.
Qin X, Tran B, Kim M, Wang L, Nguyen D, Chen Q, et al.
Int J Antimicrob Agents
. 2017 Apr;
49(5):579-588.
PMID: 28363526
Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023) assessed the efficacy and safety of ceftazidime/avibactam plus metronidazole compared with...
8.
Maertens J, Madero L, Reilly A, Lehrnbecher T, Groll A, Jafri H, et al.
Pediatr Infect Dis J
. 2010 May;
29(5):415-20.
PMID: 20431381
Background: Persistently febrile neutropenic children at risk for invasive fungal infections receive empiric antifungal therapy as a standard of care. However, little is known about the role of echinocandins and...
9.
Toth M, Frase H, Chow J, Smith C, Vakulenko S
Antimicrob Agents Chemother
. 2010 Feb;
54(4):1590-5.
PMID: 20145089
Directed evolution by random PCR mutagenesis of the gene for the aminoglycoside 2''-IIa phosphotransferase generated R92H/D268N and N196D/D268N mutant enzymes, resulting in elevated levels of resistance to amikacin and isepamicin...
10.
Zaoutis T, Lehrnbecher T, Groll A, Steinbach W, Jafri H, Maertens J, et al.
Pediatr Infect Dis J
. 2009 Sep;
28(12):1132-5.
PMID: 19779392
We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean...